Correspondence | Published:

Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44:1179–81.

  2. 2.

    Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.

  3. 3.

    Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.

  4. 4.

    Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–8.

  5. 5.

    Buscarlet M, Provost S, Zada YF, Barhdadi A, Bourgoin V, Lépine G, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130:753–62.

  6. 6.

    Arends CM, Galan-Sousa J, Hoyer K, Chan W, Jäger M, Yoshida K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018;32:1908–19.

  7. 7.

    Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21.

  8. 8.

    Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21:374–82.

  9. 9.

    Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35:1598–605.

  10. 10.

    Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–7.

  11. 11.

    Tichelli A, Passweg J, Wójcik D, Rovó A, Harousseau J-L, Masszi T, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:1203–10.

  12. 12.

    Martin PJ, Counts GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28:1011–6.

  13. 13.

    Collord G, Park N, Podestà M, Dagnino M, Cilloni D, Jones D, et al. Clonal haematopoiesis is not prevalent in survivors of childhood cancer. Br J Haematol. 2018;181:537–9.

  14. 14.

    Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37:375–85.

  15. 15.

    Grimm J, Bill M, Jentzsch M, Beinicke S, Häntschel J, Goldmann K, et al. Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. Bone Marrow Transpl. 2018.

Download references


The authors thank Irmgard Matt (Department of Medicine I, Medical Center – University of Freiburg) for providing the clinical information on the patients and PD Dr. Alexandra Nieters, University of Freiburg for the permission to use the PyroMark instrument. The research was supported by the Translational Research Training in Hematology (TRTH) of the European Hematology Association (EHA) and American Society of Hematology (ASH) (to HB), the German Research Foundation [DFG; FOR 2674 BE 6461/1-1 (to HB), LU 429/16-1 (to ML)], the German Cancer Aid [111210 (to HB)] and the Böhringer Ingelheim Foundation [Exploration Grant (to HB)].

Author information

AH: conception and design; specimen acquisition and processing; next generation sequencing (NGS) data acquisition, analyses and interpretation; analysis coordination. JW: NGS data analyses and interpretation. JS: specimen processing; NGS and conventional sequencing data acquisition and analyses. CN: specimen processing; NGS and conventional sequencing data acquisition and analyses. SB: specimen processing; conventional sequencing data acquisition and analyses. MW: specimen acquisition and processing; chimerism data acquisition and interpretation. DU: conventional sequencing data acquisition and analyses. KHM: conception and design. ML: conception and design; patient care; specimen acquisition; data interpretation. JD: conception and design; data interpretation. JF: conception and design; patient care; specimen acquisition; data interpretation. HB: conception and design; patient care; specimen acquisition; data acquisition, analyses and interpretation; analysis coordination; manuscript preparation.

Correspondence to Heiko Becker.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplemental Material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark